The Role of the Glymphatic System Avaluated Thourgh mr Imaging in the Diagnosis and Management of NPH
Key facts
- Who runs it
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 29 people enrolled
- Started
- 15 Jun 2021
- Ended
- 31 Dec 2024
- Type of study
- Observational, 2 groups
- Record updated
- 11 February 2026
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- clinical and radiological diagnosis of probable NPH according to existing guidelines
- age of over 50 years
Who cannot take part
- previous neurosurgical interventions on the brain of any type
- inability to undergo MR
- diagnosis of any other neurological pathology, particularly neurodegenerative or neuroinflammatory
- inability to undergo general anaesthesia
Other criteria
- Suspected NPH patients according to the following:
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational study is to evaluate the role of DTI-ALPS in the diagnostic and therapeutic management of NPH
Read full original descriptionShow less
The main questions it aims to answer are:
* Whether the glymphatic system (GS) is actually impaired in NPH * Whether DTI-ALPS index can predict the positive response to tap test (TT) and to ventriculo-peritoneal shunt (VPS) surgery.
A healthy control group of patients (HC group) matched for age with the study group, will undergo MR with DTI-ALPS study
The 2 groups in the trial
- Study group
Patients attending the NPH outpatient clinic were prospectively enrolled in the study. The inclusion criteria were: (i) clinical and radiological diagnosis of probable NPH according to existing guidelines and (ii) age of over 50 years. Exclusion criteria were: (i) inability to undergo MR; (ii) a diagnosis of any other neurological pathology, particularly neurodegenerative or neuroinflammatory; (iii) previous neurosurgical interventions on the brain of any type; (iv) inability to undergo general anaesthesia.
- Control group
A healthy control group of patients (HC group) matched for age with the IR group, underwent MR with DTI-ALPS study. Exclusion criteria for this group were: (i) a previous diagnosis of any neurological disorder of any type. (ii) a history of neurosurgical intervention of any kind; and (iii) a prior diagnosis of malignancy of any type.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 11 February 2026